Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Diagnostics & prognostics, Infectious diseases

Super Saliva Test

The advent of antiretroviral therapies to control HIV and the use of pre-exposure prophylaxis has turned a once-terminal illness into a relatively manageable disease when caught early enough. But although great strides have been made to curb the virus, 36.7 million people worldwide currently live with HIV – nearly half of whom are unsure of the status of their infection (1). Clearly, without access to adequate testing, it’s difficult for both patients and the medical community to keep track. And that’s why Carolyn Bertozzi and her team decided to develop a highly sensitive HIV assay for saliva (2)

At the moment, there are two main types of tests for screening HIV, each with pros and cons: blood tests are highly sensitive, but have a poor rate of compliance despite being minimally invasive; oral fluid tests, on the other hand, although noninvasive, typically suffer from poor sensitivity because of the lower concentrations of anti-HIV antibodies. The new oral fluid assay addresses the challenge by using antibody detection by agglutination-PCR (ADAP) – making it 1,000–10,000 times more sensitive than existing tests. “ADAP is based on the concept of proximity ligation PCR, which we knew had the capability of ultrasensitive DNA detection. This ADAP was designed to bring the sensitivity of PCR to the problem of antibody detection,” says Bertozzi, lead investigator, and Anne T. and Robert M. Bass Professor of Chemistry at Stanford University. “The ADAP test can enable earlier detection of HIV infection in the context of population screening using oral fluid, which is easier to collect and far less risky for healthcare workers because, unlike blood, oral fluid is not infectious.”

Bertozzi acknowledges that translating the research to the clinic is no small feat: “The biggest hurdles that lie ahead are larger studies with longitudinal data to judge how ADAP compares with current oral and blood-based tests.” But the team also see great promise in the ADAP assays, and plan to develop analogous tests for other infectious and autoimmune diseases that produce autoantibody biomarkers.

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. HIV.gov, “The global HIV/AIDS epidemic” (2017). Available at: bit.ly/2xpEQnn. Accessed February 1, 2018.
  2. CT Tsai et al., “Antibody detection by agglutination-PCR (ADAP) enables early diagnosis of HIV infection by oral fluid analysis”, Proc Natl Acad Sci USA, [Epub ahead of print] (2018). PMID: 29358368.
About the Author
William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Related Solution
Tools & Techniques Diagnostics & prognostics
SERS for Label-Free Biosensing

| Contributed by Ocean Optics

Most Popular
Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register